Whitehawk Therapeutics, Inc. is an oncology biotechnology company focused on the discovery and development of antibody-drug conjugate (ADC) therapies for cancer. The company’s primary objective is to leverage next-generation ADC platform technologies—engineered for greater stability and a higher therapeutic index—to address the needs of patients with challenging, treatment-resistant tumors. Its pipeline comprises three ADC assets, each designed to target clinically validated proteins that are broadly expressed across various tumor types, with a strategic emphasis on lung and gynecological cancers. Whitehawk Therapeutics employs advanced tumor biology insights to more effectively dose and deliver their therapies, aiming to overcome limitations found in earlier ADC approaches. Formerly operating under the name Aadi Bioscience, the company relaunched with a sharpened focus in March 2025, reflecting its commitment to innovation in cancer treatment. Headquartered in Morristown, New Jersey, Whitehawk Therapeutics occupies a significant niche within the healthcare and biotechnology sectors, serving as a key player in the advancement of targeted cancer therapies for patients with significant unmet medical needs.